Who are IK-3001's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): intravenous iron carboxymaltose, Iron Carboxymaltose, Ferric Carboxymaltose (FCM), Iron Sucrose (Venofer), SFP, FCM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ik-3001.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

IK-3001 — Competitive Intelligence Brief

IK-3001 (IK-3001) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous iron replacement agent. Area: Hematology.

phase 3 Intravenous iron replacement agent Iron (Fe3+) delivery system Hematology Small molecule Live · refreshed every 30 min

Target snapshot

IK-3001 (IK-3001) — Mallinckrodt. IK-3001 is an intravenous iron replacement therapy that replenishes depleted iron stores in patients with iron deficiency.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IK-3001 TARGET	IK-3001	Mallinckrodt	phase 3	Intravenous iron replacement agent	Iron (Fe3+) delivery system
intravenous iron carboxymaltose	intravenous iron carboxymaltose	University of Zurich	marketed	Intravenous iron replacement agent	Iron (Fe³⁺) delivery system; transferrin receptor-mediated uptake
Iron Carboxymaltose	Iron Carboxymaltose	Albina Nowak, MD	marketed	Intravenous iron replacement agent	Iron(III) ion; transferrin and ferritin (iron-binding proteins)
Ferric Carboxymaltose (FCM)	Ferric Carboxymaltose (FCM)	American Regent, Inc.	marketed	Intravenous iron replacement agent	Iron (Fe³⁺) delivery; transferrin and ferritin binding
Iron Sucrose (Venofer)	Iron Sucrose (Venofer)	American Regent, Inc.	marketed	Intravenous iron replacement agent
SFP	SFP	Rockwell Medical Technologies, Inc.	marketed	Intravenous iron replacement agent	Iron (Fe3+) for hemoglobin synthesis and erythropoiesis
FCM	FCM	AMAG Pharmaceuticals, Inc.	phase 3	Intravenous iron replacement agent	Iron (Fe3+) delivery via transferrin-mediated uptake

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous iron replacement agent class)

American Regent, Inc. · 2 drugs in this class
AMAG Pharmaceuticals, Inc. · 1 drug in this class
Albina Nowak, MD · 1 drug in this class
Mallinckrodt · 1 drug in this class
Rockwell Medical Technologies, Inc. · 1 drug in this class
University of Zurich · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IK-3001 — Competitive Intelligence Brief. https://druglandscape.com/ci/ik-3001. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab